OptiNose, Inc. (OPTN)
NASDAQ: OPTN · Real-Time Price · USD
0.670
-0.006 (-0.90%)
Nov 4, 2024, 4:00 PM EST - Market closed
Company Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States.
The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail.
The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
OptiNose, Inc.
Country | United States |
Founded | 2010 |
IPO Date | Oct 13, 2017 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 132 |
CEO | Ramy Mahmoud |
Contact Details
Address: 1020 Stony Hill Road, Suite 300 Yardley, Pennsylvania 19067 United States | |
Phone | 267 364 3500 |
Website | optinose.com |
Stock Details
Ticker Symbol | OPTN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001494650 |
CUSIP Number | 68404V100 |
ISIN Number | US68404V1008 |
Employer ID | 42-1771610 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Ramy A. Mahmoud M.D., M.P.H. | Chief Executive Officer and Director |
Michael F. Marino Esq. | Chief Legal Officer and Corporate Secretary |
Paul Spence | Chief Commercial Officer |
P. Terence Kohler | Chief Financial Officer |
Anthony J. Krick | Vice President of Finance and Chief Accounting Officer |
Jonathan Neely | Vice President of Investor Relations and Business Development |
Karen E. Brophy | Chief Human Resources Officer and Vice President of Human Resources |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Oct 16, 2024 | 8-K | Current Report |
Oct 8, 2024 | 8-K | Current Report |
Sep 25, 2024 | 8-K | Current Report |
Sep 16, 2024 | 144 | Filing |
Sep 16, 2024 | 144 | Filing |
Aug 8, 2024 | 10-Q | Quarterly Report |
Aug 8, 2024 | 8-K | Current Report |
Jul 15, 2024 | 144 | Filing |
Jul 15, 2024 | 144 | Filing |